These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Anti-α-enolase antibody combined with β2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients.
    Author: Huang Y, Chen L, Chen K, Huang F, Feng Y, Xu Z, Wang W.
    Journal: Lupus; 2019 Mar; 28(3):365-370. PubMed ID: 30813870.
    Abstract:
    OBJECTIVE: Anti-α-enolase antibody (Ab) combined with β2 microglobulin (β2-MG) were investigated to predict the incidence of nephritis in systemic lupus erythematosus (SLE) patients. METHODS: Levels of serum anti-α-enolase Ab and urinary β2-MG were detected in 115 SLE patients, 29 SLE patients with nephritis and 70 healthy controls by ELISA and immunoturbidimetry, respectively. Furthermore, the correlation between anti-α-enolase Ab combined with β2-MG and the incidence of nephritis in SLE patients was evaluated by correlation analysis. RESULTS: The optical density value of serum anti-α-enolase Ab in SLE patients with nephritis (0.84) was greatly increased compared with SLE patients (0.76) or healthy controls (0.54). Moreover, the levels of urinary β2-MG in SLE patients with nephritis (6.75 mg/L) were increased compared with SLE patients (3.45 mg/L) or healthy controls (1.48 mg/L). There was a positive correlation between the level of anti-α-enolase Ab and β2-MG ( r = 0.754). Furthermore, anti-α-enolase Ab combined with β2-MG for evaluating the incidence of nephritis in SLE patients had the best assessment of the effectiveness (area under the receiver operating characteristic curve (AUC): 92.7%) compared with only anti-α-enolase Ab (AUC: 80.9%) or β2-MG (AUC: 84.5%). CONCLUSION: These data suggested that anti-α-enolase Ab may be a potential indicator for the prediction of nephritis in SLE patients.
    [Abstract] [Full Text] [Related] [New Search]